{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:57:21Z","timestamp":1791219441422,"version":"4.1.0"},"reference-count":59,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["765394"],"award-info":[{"award-number":["765394"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TRANSCAN-2","award":["TRS-2016-00000371"],"award-info":[{"award-number":["TRS-2016-00000371"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["CP19\/00114"],"award-info":[{"award-number":["CP19\/00114"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["FI20\/00058"],"award-info":[{"award-number":["FI20\/00058"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI16\/00668"],"award-info":[{"award-number":["PI16\/00668"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI19\/01128"],"award-info":[{"award-number":["PI19\/01128"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI20\/00002"],"award-info":[{"award-number":["PI20\/00002"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["0011-1408-2016-000002"],"award-info":[{"award-number":["0011-1408-2016-000002"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["0011-1411-2020-000075"],"award-info":[{"award-number":["0011-1411-2020-000075"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AECC-2019 Investigator"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,6,27]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Modified vaccinia virus Ankara (MVA) are genetically engineered non-replicating viral vectors. Intratumoral administration of MVA induces a cyclic GMP-AMP synthase-mediated type I interferon (IFN) response and the production of high levels of the transgenes engineered into the viral genome such as tumor antigens to construct cancer vaccines. Although type I IFNs are essential for establishing CD8-mediated antitumor responses, this cytokine family may also give rise to immunosuppressive mechanisms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In vitro assays were performed to evaluate the activity of simvastatin and atorvastatin on type I IFN signaling and on antigen presentation. Surface levels of IFN \u03b1\/\u03b2 receptor 1, endocytosis of bovine serum albumin-fluorescein 5 (6)-isothiocyanate, signal transducer and activator of transcription (STAT) phosphorylation, and real-time PCR of IFN-stimulated genes were assessed in the murine fibroblast cell line L929. In vivo experiments were performed to characterize the effect of simvastatin on the MVA-induced innate immune response and on the antitumor effect of MVA-based antitumor vaccines in B16 melanoma expressing ovalbumin (OVA) and Lewis lung carcinoma (LLC)-OVA tumor models. RNAseq analysis, depleting monoclonal antibodies, and flow cytometry were used to evaluate the MVA-mediated immune response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this work, we identified commonly prescribed statins as potent IFN\u03b1 pharmacological inhibitors due to their ability to reduce surface expression levels of IFN-\u03b1\/\u03b2 receptor 1 and to reduce clathrin-mediated endocytosis. Simvastatin and atorvastatin efficiently abrogated for 8\u2009hours the transcriptomic response to IFN\u03b1 and enhanced the number of dendritic cells presenting an OVA-derived peptide bound to major histocompatibility complex (MHC) class I. In vivo, intraperitoneal or intramuscular administration of simvastatin reduced the inflammatory response mediated by peritumoral administration of MVA and enhanced the antitumor activity of MVA encoding tumor-associated antigens. The synergistic antitumor effects critically depend on CD8<jats:sup>+<\/jats:sup> cells, whereas they were markedly improved by depletion of CD4<jats:sup>+<\/jats:sup> lymphocytes, T regulatory cells, or NK cells. Either MVA-OVA alone or combined with simvastatin augmented B cells, CD4<jats:sup>+<\/jats:sup> lymphocytes, CD8<jats:sup>+<\/jats:sup> lymphocytes, and tumor-specific CD8<jats:sup>+<\/jats:sup> in the tumor-draining lymph nodes. However, only the treatment combination increased the numbers of these lymphocyte populations in the tumor microenvironment and in the spleen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In conclusion, blockade of IFN\u03b1 functions by simvastatin markedly enhances lymphocyte infiltration and the antitumor activity of MVA, prompting a feasible drug repurposing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001587","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T13:24:31Z","timestamp":1627478671000},"page":"e001587","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors"],"prefix":"10.1136","volume":"9","author":[{"given":"Shirley","family":"Tenesaca","sequence":"first","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Vasquez","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-9181","authenticated-orcid":false,"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Otano","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Fernandez-Sendin","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Augusta","family":"Di Trani","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Ardaiz","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Gomar","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bella","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Aranda","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Medina-Echeverz","sequence":"additional","affiliation":[{"name":"Bavarian Nordic GmbH, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"},{"name":"Department of Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-1865","authenticated-orcid":false,"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"2025100312172304000_9.7.e001587.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2025100312172304000_9.7.e001587.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100312172304000_9.7.e001587.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100312172304000_9.7.e001587.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2025100312172304000_9.7.e001587.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3770"},{"key":"2025100312172304000_9.7.e001587.6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5025","article-title":"Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade","volume":"11","author":"Shekarian","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025100312172304000_9.7.e001587.7","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910375","article-title":"Repurposing the yellow fever vaccine for intratumoral immunotherapy","volume":"12","author":"Aznar","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2025100312172304000_9.7.e001587.8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","article-title":"Dna sensing by the cGAS-STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat Rev Genet"},{"key":"2025100312172304000_9.7.e001587.9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aal1713","article-title":"Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via sting and Batf3-dependent dendritic cells","volume":"2","author":"Dai","year":"2017","journal-title":"Sci Immunol"},{"key":"2025100312172304000_9.7.e001587.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.015"},{"key":"2025100312172304000_9.7.e001587.11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2018.132","article-title":"An RNA toolbox for cancer immunotherapy","volume":"17","author":"Pastor","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2025100312172304000_9.7.e001587.12","doi-asserted-by":"crossref","first-page":"77245","DOI":"10.1016\/j.cyto.2015.08.258","article-title":"Endogenous and pharmacologic targeting of the sting pathway in cancer immunotherapy","volume":"77","author":"Corrales","year":"2016","journal-title":"Cytokine"},{"key":"2025100312172304000_9.7.e001587.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1114"},{"key":"2025100312172304000_9.7.e001587.14","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040664"},{"key":"2025100312172304000_9.7.e001587.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0328-y"},{"key":"2025100312172304000_9.7.e001587.16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.227"},{"key":"2025100312172304000_9.7.e001587.17","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djy033","article-title":"Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy","volume":"110","author":"Kurokawa","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2025100312172304000_9.7.e001587.18","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-15-0427"},{"key":"2025100312172304000_9.7.e001587.19","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"2025100312172304000_9.7.e001587.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912344107"},{"key":"2025100312172304000_9.7.e001587.21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1613","article-title":"Dimethyl fumarate potentiates oncolytic virotherapy through NF-\u03baB inhibition","volume":"10","author":"Selman","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025100312172304000_9.7.e001587.22","doi-asserted-by":"crossref","DOI":"10.1038\/srep26786","article-title":"First-In-Class small molecule potentiators of cancer virotherapy","volume":"6","author":"Dornan","year":"2016","journal-title":"Sci Rep"},{"key":"2025100312172304000_9.7.e001587.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl445"},{"key":"2025100312172304000_9.7.e001587.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-009-0038-5"},{"key":"2025100312172304000_9.7.e001587.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.08.070","article-title":"The mevalonate pathway is a druggable target for vaccine adjuvant discovery","volume":"175","author":"Xia","year":"2018","journal-title":"Cell"},{"key":"2025100312172304000_9.7.e001587.26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.614250","article-title":"Infusion of host-derived unlicensed NK cells improves donor engraftment in non-myeloablative allogeneic hematopoietic cell transplantation","volume":"11","author":"Alvarez","year":"2020","journal-title":"Front Immunol"},{"key":"2025100312172304000_9.7.e001587.27","article-title":"Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway","volume":"5","author":"Alvarez","year":"2019","journal-title":"JCI Insight"},{"key":"2025100312172304000_9.7.e001587.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0321"},{"key":"2025100312172304000_9.7.e001587.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05347-6"},{"key":"2025100312172304000_9.7.e001587.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0439-x"},{"key":"2025100312172304000_9.7.e001587.31","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E06-01-0076"},{"key":"2025100312172304000_9.7.e001587.32","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12001"},{"key":"2025100312172304000_9.7.e001587.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_134.x"},{"key":"2025100312172304000_9.7.e001587.34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1196309","article-title":"Interferon alpha bioactivity critically depends on scavenger receptor class B type I function","volume":"5","author":"Vasquez","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100312172304000_9.7.e001587.35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.5986"},{"key":"2025100312172304000_9.7.e001587.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035"},{"key":"2025100312172304000_9.7.e001587.37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01617-08"},{"key":"2025100312172304000_9.7.e001587.38","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01097-19","article-title":"Interference with SAMHD1 restores late gene expression of modified vaccinia virus Ankara in human dendritic cells and abrogates type I interferon expression","volume":"93","author":"Sliva","year":"2019","journal-title":"J Virol"},{"key":"2025100312172304000_9.7.e001587.39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24306"},{"key":"2025100312172304000_9.7.e001587.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y"},{"key":"2025100312172304000_9.7.e001587.41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0933"},{"key":"2025100312172304000_9.7.e001587.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.01.006"},{"key":"2025100312172304000_9.7.e001587.43","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0677-y"},{"key":"2025100312172304000_9.7.e001587.44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","article-title":"CD25-T\n                  reg\n               -depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity","volume":"1","author":"Solomon","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100312172304000_9.7.e001587.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.05.003"},{"key":"2025100312172304000_9.7.e001587.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.05.004"},{"key":"2025100312172304000_9.7.e001587.47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400034"},{"key":"2025100312172304000_9.7.e001587.48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082387"},{"key":"2025100312172304000_9.7.e001587.49","first-page":"3304","article-title":"Cutting edge: CD8 + T cell priming in the absence of NK cells leads to enhanced memory responses","volume":"186","author":"Soderquest","year":"2011","journal-title":"J.i."},{"key":"2025100312172304000_9.7.e001587.50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222190"},{"key":"2025100312172304000_9.7.e001587.51","doi-asserted-by":"publisher","DOI":"10.3747\/co.2008.200"},{"key":"2025100312172304000_9.7.e001587.52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102495"},{"key":"2025100312172304000_9.7.e001587.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.05.005"},{"key":"2025100312172304000_9.7.e001587.54","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdy089","article-title":"Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients","volume":"29","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100312172304000_9.7.e001587.55","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25333"},{"key":"2025100312172304000_9.7.e001587.56","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26412"},{"key":"2025100312172304000_9.7.e001587.57","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.465"},{"key":"2025100312172304000_9.7.e001587.58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.antiviral.2013.04.009","article-title":"Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis","volume":"98","author":"Zhu","year":"2013","journal-title":"Antiviral Res"},{"key":"2025100312172304000_9.7.e001587.59","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70144-2"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:17:33Z","timestamp":1759519053000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,28]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/jitc-2020-001587"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001587","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}